Cortes JE, Lang F, Rea D, Hochhaus A, et al. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia 2025 Apr 9. doi: 10.1038/s41375-025-02592.
PMID: 40204896